In some cases, mesothelin expression has been associated with increased tumor aggressiveness and poor clinical outcome, however, its impact on the clinical outcome of malignant pleural mesothelioma patients has not been extensively evaluated [3–10]. This evidence concerns the gene MSLN and neoplasm.